Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS AstraZeneca Crowned in Foreign Pharma Ranking for 2nd Year Straight, Followed by MSD
June 9, 2023
-
REGULATORY Honebuto Social Security Debate Culminates with LDP Push for Nixing Budget Cap
June 9, 2023
-
REGULATORY Sumitomo to Urge Switch from Noritren over Carcinogen Risks, but Continues Shipments
June 8, 2023
-
REGULATORY Draft Honebuto Paper Unveiled, Cabinet OK Expected in Mid-June
June 8, 2023
-
REGULATORY Draft Honebuto Paper Calls for Further Drug Pricing Measures to Reward Innovation
June 7, 2023
-
ORGANIZATION Industry’s Concerns Beginning to Sink in among Policymakers: JPMA Committee Chair
June 7, 2023
-
BUSINESS Japan Firms Joining Fray in siRNA Drug Development; Takeda Could File as Early as FY2025
June 6, 2023
-
REGULATORY Expert Panel to Propose Setting Up Requirements for Generic Entry to Ensure Stable Supplies; Draft Report Due Out June 6
June 5, 2023
-
REGULATORY Expert Panel Pushes Fresh Evaluation Approach for New Drug Pricing, Rethink of Spillovers: Draft Report
June 5, 2023
-
BUSINESS Shionogi Shoots for Doubling Revenue to 800 Billion Yen by FY2030
June 2, 2023
-
BUSINESS Pharma Companies in Japan Raising Retirement Age, Extending Rehiring: Jiho Poll
June 1, 2023
-
BUSINESS AbbVie Aims to Double Japan Sales to 200 Billion Yen by 2030: Local Chief
May 31, 2023
-
REGULATORY Japan to Launch New Forum to Spur Secondary Use of Medical Data in Drug Discovery
May 30, 2023
-
REGULATORY MOF Panel Flags Japan’s High Drug Cost per Capita, Stays Pat on Cost-Effectiveness-Based Reimbursement, Copay Review
May 30, 2023
-
BUSINESS Jeremy Grossas to Head Up Merck Biopharma Japan
May 30, 2023
-
REGULATORY PM Advisors Make Irregular Call for Properly Rewarding Innovation to Boost Japan’s Drug Discovery Capabilities
May 29, 2023
-
REGULATORY Gene Therapy Luxturna Now in Line for Approval in June
May 29, 2023
-
BUSINESS Pfizer Japan Files RSV Vaccine for 60 Years of Age and Older
May 29, 2023
-
ORGANIZATION New JPMA Chief Renews Resolve for Drug Price Maintenance, Dynamic Policies
May 26, 2023
-
ORGANIZATION Mitsubishi Tanabe’s Ueno Elected as New JPMA President
May 26, 2023
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…